Navigation Links
Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/15/2009

HOPKINTON, Mass., Jan. 15 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced preliminary revenue results for its 2008 fourth quarter and full year ended December 31, 2008.

Based on the company's preliminary financial results, total revenue is expected to be approximately $36.5 million for the fourth quarter of 2008 and approximately $133.9 million for the full year, which is at the upper end of the company's previous revenue guidance for the fourth quarter of $34 million to $37 million.

Earlier in the fourth quarter, Caliper announced the sale of its Pharmaceutical Development & Quality and AutoTrace product lines in transactions valued in the aggregate at approximately $21.0 million. 2008 pro forma revenue, reflecting the divestiture of these two product lines, for the fourth quarter and full year is expected to be approximately $34.6 million and $122.8 million, respectively.

Fourth quarter and full year preliminary revenue results are pending finalization of the company's financial results for the quarter and year ended December 31, 2008 and accordingly are subject to change.

2009 Revenue Guidance

For 2009, Caliper currently expects total revenue to increase by approximately 4% to 7% compared with 2008 pro forma revenue, with the growth primarily occurring in the second half of the year. The company cited currency headwinds as a key factor influencing its estimates.

Presentation at Today's J.P. Morgan Conference

As announced in a separate press release issued by the company on December 23, 2008, Caliper will today make a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California. A live webcast of the company's presentation can be accessed at http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=CALP. An archived edition of the presentation will be available for 90 days.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding Caliper's anticipated total revenue for the fourth quarter of 2008 and for 2008 and its expected revenue results for 2009 are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those Caliper expects or projects, including the risks that unexpected information may be received, or adjustments may be made, in the course of finalizing and analyzing the financial results, which could cause the final results to differ from these preliminary results. Finalization of the company's financial results for 2008 could lead to revisions in the company's current expectations regarding revenue for the quarter and year ended December 31, 2008 and the year ending December 31, 2009. Further information on risks faced by Caliper is included in risks discussed under the caption "Risk Factors" in Caliper's annual report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 14, 2008, and in our other SEC reports and filings. These SEC reports and filings are available on a web site maintained by the SEC at http://www.sec.gov. Caliper expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Caliper's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Caliper is a registered trademark of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
2. Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line
3. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
4. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
5. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
6. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
7. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
8. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
9. Caliper Life Sciences Reports Second Quarter 2008 Results
10. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
11. Caliper Life Sciences Added to Russell 3000(R) Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 ... ... launch of a redesigned, easier-to-navigate website for all six of their healthcare ... physicians, nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and ...
(Date:6/22/2017)... Colorado (PRWEB) , ... June 21, 2017 , ... ... RTP regional office in North Carolina, and engages Timothy Reinhardt to manage the ... of quality leadership at Pfizer Inc, with his most recent role as the ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation ... infertility as a disease, bringing new hope for prospective parents who are challenged ... meeting to back the World Health Organization’s designation in hopes of changing the ...
(Date:6/22/2017)... ... , ... The first human cell line HeLa, established in 1951, has entered ... of human cell lines with HeLa cells were published. Until recently, cross-contamination and misidentification ... is associated with dramatic consequences for research. , In this educational webinar, which ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):